Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of drugs. The company was formerly known as Sunshine Lake Pharma Ltd. The company was founded in 2003 and is based in Dongguan, China.
Metrics to compare | 1558 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1558PeersSector | |
---|---|---|---|---|
P/E Ratio | 26.5x | −21.4x | −0.5x | |
PEG Ratio | −0.35 | 0.02 | 0.00 | |
Price/Book | 1.5x | 3.2x | 2.6x | |
Price / LTM Sales | 3.4x | 6.9x | 3.3x | |
Upside (Analyst Target) | −11.1% | −9.0% | 43.5% | |
Fair Value Upside | Unlock | −14.8% | 6.8% | Unlock |